Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Nilanjan Ghosh

Nilanjan Ghosh

MD, PhD
Levine Cancer Institute
Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL 6:42
Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL
Nilanjan Ghosh • 10 Dec 2025
Evaluation of real-world venetoclax initiation prophylaxis & monitoring outcomes in CLL 2:31
Evaluation of real-world venetoclax initiation prophylaxis & monitoring outcomes in CLL
Nilanjan Ghosh • 10 Dec 2025
Key takeaways & trials from ICML in DLBCL, MCL, and FL: POLARGO, STARGLO, MorningSun & more 15:00
Key takeaways & trials from ICML in DLBCL, MCL, and FL: POLARGO, STARGLO, MorningSun & more
Nilanjan Ghosh • 27 Jun 2025
The effectiveness of ibrutinib flexible dosing regimens on TTNT in CLL/SLL 2:24
The effectiveness of ibrutinib flexible dosing regimens on TTNT in CLL/SLL
Nilanjan Ghosh • 26 Jun 2024
An overview of CAR T-cell therapies in the treatment of patients with MCL 6:46
An overview of CAR T-cell therapies in the treatment of patients with MCL
Nilanjan Ghosh • 26 Jun 2024
The real-world effectiveness of venetoclax-based therapy after BTKis in patients with CLL 3:50
The real-world effectiveness of venetoclax-based therapy after BTKis in patients with CLL
Nilanjan Ghosh • 26 Jun 2024
Real-world data on the effect of ibrutinib flexible dosing treatment strategies on TTNT in CLL/SLL 6:05
Real-world data on the effect of ibrutinib flexible dosing treatment strategies on TTNT in CLL/SLL
Nilanjan Ghosh • 14 Dec 2023
Treatment effectiveness of venetoclax-based therapy after BTKi exposure in CLL/SLL 5:45
Treatment effectiveness of venetoclax-based therapy after BTKi exposure in CLL/SLL
Nilanjan Ghosh • 14 Dec 2023
Comparative effectiveness of liso-cel vs conventional 2L chemotherapy in R/R LBCL 5:42
Comparative effectiveness of liso-cel vs conventional 2L chemotherapy in R/R LBCL
Nilanjan Ghosh • 8 Dec 2022
InformCLL registry analysis: ibrutinib vs chemoimmunotherapy for the first-line treatment of CLL/SLL 5:59
InformCLL registry analysis: ibrutinib vs chemoimmunotherapy for the first-line treatment of CLL/SLL
Nilanjan Ghosh • 8 Dec 2022
Genomic testing in CLL & uptake in community practices 2:33
Genomic testing in CLL & uptake in community practices
Nilanjan Ghosh • 8 Dec 2022
Mechanisms of resistance to immunotherapy in NHL 1:52
Mechanisms of resistance to immunotherapy in NHL
Nilanjan Ghosh • 10 Jun 2022
Novel agents in development for the treatment of MCL 2:18
Novel agents in development for the treatment of MCL
Nilanjan Ghosh • 10 Jun 2022
PILOT study – patient characteristics and key results 1:17
PILOT study – patient characteristics and key results
Nilanjan Ghosh • 10 Jun 2022
Primary analysis of the Phase II PILOT study: liso-cel as second-line therapy for R/R LBCL 6:13
Primary analysis of the Phase II PILOT study: liso-cel as second-line therapy for R/R LBCL
Nilanjan Ghosh • 10 Jun 2022
The current and future ADC treatment landscape for lymphoma 9:09
The current and future ADC treatment landscape for lymphoma
Nilanjan Ghosh • 24 Jun 2021
The content of VJHemOnc is intended for healthcare professionals